Data Platform as a Service (dPaaS) Accelerates Time to Market


A new model of aggregating, harmonizing and analyzing healthcare data is giving pharma companies unprecedented ability to both reduce development costs and to accelerate the time bringing new drugs to market.
 
Called dPaaS for Data Platform as a Service cloud-based model puts the focus on data being at the center of the business universe rather than applications. This means that regardless of what application is required, access to data is always available. More often than not today, we have applications that create boundaries around data rather than making data accessible for all business needs. Not only does dPaaS provide maximum flexibility and scale for pharma researchers, but it allows expert scientists to use their time and skills wisely toward actual drug development, rather than serving as high-cost “data janitors” in cleaning and preparing their data for analysis.
[Read more…]

Creating a Compliant Culture


Creating a compliant culture: In this age of distributed data sources, commercialization of IT with “bring your own devices,” the demands of business to get faster and unrestricted access to data, compliance teams are more challenged than ever before. The reality is that although the onus of compliance and regulatory reporting fall to the select few within the enterprise that bear that title, being knowledgeable about best practices in handling sensitive data, and doing business in a compliant way is everyone’s responsibility.
[Read more…]

FDA Warning Letters: Alerting Signs are Always There


Keep an eye for the warning signs in your internal procedures and processes to reduce the risk of being caught by the FDA.
 
Oops! I got the FDA warning letter. Now what should I do?  How should I respond to prevent further enforcement actions by the Agency?  And all the other barrage of questions scares you. Look at it differently.  How do you foresee that a warning letter is coming? What are the signs that can help you anticipate a letter from the Agency? If you can do that, then hopefully, you can take steps to avoid one and resolve it before FDA knocks your door.

Warning Letter Trends

In the recent past the FDA has made an effort to speed up the warning letter program. This means that they will no longer build an airtight legal case before issuing the letter. Multiple warning letters are also no longer being issued. In some cases, the FDA has shown that it will not even issue a formal letter before shutting down a facility, recalling products or revoking licenses.
[Read more…]

Does Your Incentive Compensation Plan Need a New Prescription?


In today’s regulatory environment, the pharmaceutical sales incentive plan is one area that receives deserved close scrutiny by compliance departments. The reason? A company’s incentive plan can be used as evidence of encouraging non-compliant behavior, especially around off-label promotion. Due to the risks this creates, it is crucial that companies demonstrably encourage a culture of compliance, implementing compliance-cautious strategies for compensating their sales force.
[Read more…]

China’s Regulatory Review on New Drugs and Oncology Market


China poses new and unique compliance challenges for pharmaceutical companies that are aiming to work in the country. The Chinese government has been proactive in approving new, safe pharmaceuticals quickly, as well as in protecting its population. There is a dire need for oncology pharmaceuticals, especially for lung cancer, as it is the most prevalent type in China, according to China’s 2015 cancer statistics report. There are many factors concerning China’s regulatory review on new drugs and the oncology market to understand when entering this market.
[Read more…]

Paradigm Shift – Project-based Engagement to SLA/Capacity-based Compliance Outsourcing


Life science companies are still struggling to find the right balance in managing IT compliance, quality and cost. They must meet compliance requirements for multiple regulations, while at the same time are under significant pressure to cut costs, reduce permanent staff, and outsource activities that are not part of their core business. Compliance costs are considered a significant overhead, especially when not done effectively. To optimize these costs while increasing work quality, firms are moving away from project-based engagements to service level agreement (SLA)/capacity-based models.
[Read more…]